DE69524393D1 - Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen durch die Absetzung von Arzenei/Zyklodextrin Komplexe auf inerte oder aktive Kerne - Google Patents

Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen durch die Absetzung von Arzenei/Zyklodextrin Komplexe auf inerte oder aktive Kerne

Info

Publication number
DE69524393D1
DE69524393D1 DE69524393T DE69524393T DE69524393D1 DE 69524393 D1 DE69524393 D1 DE 69524393D1 DE 69524393 T DE69524393 T DE 69524393T DE 69524393 T DE69524393 T DE 69524393T DE 69524393 D1 DE69524393 D1 DE 69524393D1
Authority
DE
Germany
Prior art keywords
inert
solution
deposition
pharmaceutical compositions
active cores
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69524393T
Other languages
English (en)
Other versions
DE69524393T2 (de
Inventor
Sousa Goucha Jorge Pedro Ma De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tecnimede Sociedade Tecnico Medicinal SA
Original Assignee
Tecnimede Sociedade Tecnico Medicinal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8221680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69524393(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tecnimede Sociedade Tecnico Medicinal SA filed Critical Tecnimede Sociedade Tecnico Medicinal SA
Publication of DE69524393D1 publication Critical patent/DE69524393D1/de
Application granted granted Critical
Publication of DE69524393T2 publication Critical patent/DE69524393T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE69524393T 1995-05-29 1995-05-29 Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen durch die Absetzung von Arzenei/Zyklodextrin Komplexe auf inerte oder aktive Kerne Expired - Fee Related DE69524393T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95670004A EP0745381B1 (de) 1995-05-29 1995-05-29 Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen durch die Absetzung von Arzenei/Zyklodextrin Komplexe auf inerte oder aktive Kerne

Publications (2)

Publication Number Publication Date
DE69524393D1 true DE69524393D1 (de) 2002-01-17
DE69524393T2 DE69524393T2 (de) 2002-09-19

Family

ID=8221680

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69524393T Expired - Fee Related DE69524393T2 (de) 1995-05-29 1995-05-29 Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen durch die Absetzung von Arzenei/Zyklodextrin Komplexe auf inerte oder aktive Kerne

Country Status (5)

Country Link
EP (1) EP0745381B1 (de)
AT (1) ATE209904T1 (de)
DE (1) DE69524393T2 (de)
ES (1) ES2169114T3 (de)
PT (1) PT745381E (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061062A1 (en) * 1998-05-29 1999-12-02 Massachusetts Institute Of Technology Cyclodextrin complexes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0241806A1 (de) * 1986-04-14 1987-10-21 Fujisawa Pharmaceutical Co., Ltd. Transdermale Zubereitungen mit verzögerter Freisetzung

Also Published As

Publication number Publication date
PT745381E (pt) 2002-05-31
EP0745381B1 (de) 2001-12-05
EP0745381A1 (de) 1996-12-04
ES2169114T3 (es) 2002-07-01
DE69524393T2 (de) 2002-09-19
ATE209904T1 (de) 2001-12-15

Similar Documents

Publication Publication Date Title
ATE87319T1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
Yang et al. Anion effect on the nanostructure of a metal ion binding self-assembling peptide
ATE98964T1 (de) Zusammensetzungen welche komplexe von hyaluronsaeure enthalten und verfahren zu deren herstellung.
IE861813L (en) New Polysaccharide Esters and their Salts
KR910009240A (ko) 약제학적 또는 치료학적 활성제의 수송 시스템
ES449312A1 (es) Un procedimiento de obtencion de una dispersion de esferu- las.
ATE122698T1 (de) Kaskadenpolymer-gebundene komplexbildner, deren komplexe und konjugate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel.
ATE191642T1 (de) Herstellung von proteinmikrospähren, filmen und beschichtungen
CA2128244A1 (en) Solid Bodies Containing Active Substances and a Structure Consisting of Hydrophilic Macromolecules, Plus a Method of Producing Such Bodies
NO870560D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
ATE154614T1 (de) Heparinderivate und verfahren zu deren herstellung
DE59102788D1 (de) Verwendung von N-alkylierten 1,4-Dihydropyridindicarbonsäureestern als Arzneimittel, neue Verbindungen und Verfahren zu Ihrer Herstellung.
DE69113036T2 (de) Verzögerte arzneistoffabgabe durch topische anwendung bioadhäsiver liposomen.
ATE152118T1 (de) Kardioaktive 17b-(3-furyl) und 17b-(4- pyridazinyl)-5beta, 14beta-androstan derivate, verfahren zu ihrer herstellung und pharmazeutische präparate davon
ATE209904T1 (de) Verfahren zur herstellung von pharmazeutischen zusammensetzungen durch die absetzung von arzenei/zyklodextrin komplexe auf inerte oder aktive kerne
DE91409T1 (de) Carrageen enthaltende arzneimittelzusammensetzungen.
DE3638124A1 (de) Neue pharmazeutische verwendung von ebselen
ATE79551T1 (de) Verfahren zur herstellung eines komplexierten arzneimittels.
ATE132037T1 (de) Herstellung und anwendung von auf basis von cyclodextrin dispergierbaren kolloidalen vesikulär-systemen, in form von nanokapseln
ATE31002T1 (de) Verfahren zur herstellung von fluessigen pflanzenschutzmittelkombinationen.
WO2000001392B1 (de) 1-octadecyl-2-methyl-sn-glycero-3-phosphocholin (et180ch3) zur behandlung von humanen mammakarzinomen
ATE1442T1 (de) Pharmazeutisches mittel, enthaltend all-e- oder 13-z-7,8-dehydro-retinsaeure und verfahren zu seiner herstellung.
AT344885B (de) Verfahren zur herstellung von 18-arabinosyl-2-n-butyl-3,7,11,15,19,21,23,25,27,37-dekahydroxy-4,16,32,34,36-pentamethyl-tetrakonta-16,32-dien-35-o-lacton-40-guanidiniumsulfat(debrycin) enthaltenden pharmazeutischen praeparaten
JPS56150039A (en) Clathrate compound of prostacycline derivative
EP0331948B1 (de) Pharmazeutische Präparate zur transdermalen Applikation von Heparin

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee